Bayer
Bayer’s CRISPR venture opens for business in biotech hub
August 23, 2016Manufacturing and Production, Research and Development Bayer, casebia, crispr, gene editing, gene-editing
Bayer and CRISPR Therapeutics have joined together to launch Casebia Therapeutics and have chosen Cambridge, Massachusetts, as its base to …
Bayer’s liver cancer drug not cost-effective, says NICE
August 19, 2016Medical Communications, Sales and Marketing Bayer, CDF, NICE, Nexavar, lung cancer
NICE has deemed Bayer’s liver cancer drug Nexavar (sorafenib) as not cost-effective. The drug is currently available on the Cancer …
Pharma unit helps boost profits at Bayer
July 27, 2016Research and Development, Sales and Marketing Bayer, Q2, results
The pharmaceutical division at Bayer was the driving force, as the company announced a 5.7% increase in second quarter profit …
Bayer adds extra $2 billion to Monsanto bid
July 15, 2016Medical Communications, Sales and Marketing Bayer, monsanto
German pharma company Bayer (ETR: BAYN) have upped their bid for Monsanto (NYSE: MON) to $64 billion, putting pressure on …
Bayer says its Stivarga improved overall survival in liver cancer in late-stage trials
June 30, 2016Research and Development, Sales and Marketing Bayer, Stivarga, drug trial, liver cancer
German pharma and crop sciences giant Bayer (ETR: BAYN) said late-stage trials for its drug to treat liver cancer showed a …
Nice says Bayer’s Eylea not recommended as first-line treatment in draft recommendation
June 10, 2016Medical Communications, Research and Development Bayer, Eylea, NICE, recommendation, regulation
The National Institute for Health and Care Excellence (Nice) in a provisional guidance said Bayer’s (ETR: BAYN) Eylea (aflibercept) is …
Bayer, Orion to start Phase III trials for prostate cancer drug
June 3, 2016Medical Communications, Research and Development, Sales and Marketing Bayer, drug trial, orion, prostate cancer, research
German pharma and crop sciences giant Bayer (ETR: BAYN) and Orion Corp (Nasdaq Helsinki: ORNAV) have agreed to start a Phase …
Weekly Movers: XenoPort, Akari, Bayer…
May 31, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Sarepta Therapeutics, Stick Market, Stock, Xenoport, finance
Bayer-Monsanto story comes close on the heels of Sanofi-Medivation tussle as the pharma sector goes through the motions of consolidation. …
Monsanto rejects Bayer’s $62 billion offer
May 25, 2016Business Services, Research and Development, Sales and Marketing Bayer, Financial, M&A, MA, deal, monsanto
World’s largest seed maker Monsanto (NYSE: MON) has rejected the $62 billion takeover offer from Germany’s Bayer AG (ETR: BAYN) …
Bayer offers $62 billion for Monsanto in all cash deal
May 23, 2016Research and Development, Sales and Marketing Bayer, Deals, Financial, Merger & Acquisition, monsanto
German pharma and crop sciences giant Bayer (ETR: BAYN) has made an unsolicited $62 billion all-cash offer for Monsanto Co …
Bayer makes bid for Monsanto
May 19, 2016Manufacturing and Production, Sales and Marketing Bayer, agrochemical, bid, monsanto, takeover
Bayer (ETR: BAYN) has made a move to consolidate its position in the agrochemical sector with an unsolicited takeover bid …
Bayer terminates clinical trial for hypertension due to safety concerns
May 13, 2016Medical Communications, Research and Development Bayer, clinical trial, deaths, pulmonary hypertension, riociguat, safety concerns
Bayer has terminated a Phase II trial evaluating riociguat in patients with pulmonary hypertension due to fears raised by an …
Bayer’s liver cancer drug meets primary endpoint in late stage trial
May 5, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Stivarga, late stage trial, liver cancer, phase III, regorafenib, trial
Bayer has announced positive results from a late-stage trial evaluating Stivarga (regorafenib) tablets for the treatment of patients with unresectable …
Bayer’s earnings beat estimates as blockbusters shine
April 26, 2016Manufacturing and Production, Research and Development, Sales and Marketing Bayer, Eylea, Q1, Xarelto, blockbusters, growth, results, sales
Bayer (FWB: BAYN) has reported a 15.7% rise in underlying core earnings for the first quarter of 2016, with prescription …
Bayer says its Xarelto shows lower risk of stroke, brain haemorrhage for irregular heart rhythm condition vs BMS’ Coumadin
April 19, 2016Manufacturing and Production, Research and Development Bayer, Bristol-Myers Squibb, anti blood-clot, drug trial
New trials for anti blood-clotting drug Xarelto (rivaroxaban) showed lower risk of stroke and haemorrhage in patients with irregular heart …
Latest content
